Cash Flow Statement (Annual)

HEI / HEICO Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss 72,355 95,453 106,675 124,561 138,772 153,564 176,150 207,660
  Net Cash Provided By Used In Operating Activities Continuing Operations - 125,518 138,585 131,836 190,689 172,863 249,184 -
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 17,597 18,543 30,656 36,790 47,757 47,907 60,277 64,823
    Deferred Tax Expense From Stock Options Exercised - 7,703 13,164 5,191 93 1,402 868 0
    Defined Contribution Plan Employer Discretionary Contribution Amount - - 982 2,985 6,302 6,125 7,020 7,768
    Foreign Currency Transaction Gain Loss Before Tax - - - - - 3,704 -13 -3,347
    Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 - - - - 28,126 - - -
    Value Of Shares Issuedto Defined Contribution Plan - 0 982 2,985 - - - -
    Foreign Currency Transaction Loss Before Tax - - - - - - 13 -
    Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 - -1,150 119 -1,640 -28,126 293 3,063 1,100
    Foreign Currency Transaction Gain Before Tax - - - 0 0 3,704 - -
    Impairment Of Intangible Assets Excluding Goodwill 1,438 4,987 0 0 15,000 0 0 -
    Paymentof Contingent Considerationin Excessof Acquisition Date Value - - - - - - 631 -
    Deferred Income Tax Expense Benefit 1,817 29 -2,834 -5,785 -16,745 -7,080 -9,194 -11,096
    Tax Benefit From Stock Options Exercised1 951 7,703 - - - - - -
    Tax Benefit From Stock Options Exercised - - - - - - - -
    Excess Tax Benefit From Share Based Compensation Operating Activities -669 6,346 12,110 5,126 93 1,402 881 0
    Stock Option Plan Expense 1,353 2,647 3,948 5,117 6,426 6,048 6,434 7,415
    Increase Decrease In Operating Capital
      Increase Decrease In Receivables -10,684 5,327 5,782 16,585 -6,999 22,572 15,955 -2,846
      Increase Decrease In Other Noncurrent Assets And Liabilities Net - - -1,113 -653 -5,262 1,623 1,999 2,159
      Increase Decrease In Inventories 6,359 9,405 7,484 14,877 -126 10,187 14,421 21,204
      Increase Decrease In Prepaid Deferred Expense And Other Assets 549 343 1,072 4,918 -8,033 -1,433 2,356 -134
      Increase Decrease In Accounts Payable 125 7,257 4,269 -23 2,511 3,169 4,074 6,386
      Increase Decrease In Accrued Liabilities 11,474 10,425 5,182 12,766 -3,090 -883 35,279 1,794
      Increase Decrease In Accrued Income Taxes Payable -1,196 1,516 1,759 -7,273 1,462 373 1,443 6,071
    Other Noncash Income Expense 248 471 -1,113 -653 - - - -
  Net Cash Provided By Used In Operating Activities 101,717 125,518 - - - 172,863 249,184 274,885
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Businesses Net Of Cash Acquired 39,061 94,655 197,285 222,638 8,737 166,784 263,811 418,265
  Net Cash Provided By Used In Investing Activities Continuing Operations - -103,900 -212,708 -241,308 -25,187 -186,006 -297,616 -
  Payments To Acquire Property Plant And Equipment 8,877 9,446 15,262 18,328 16,410 18,249 30,863 25,998
  Payments For Proceeds From Other Investing Activities 325 -201 161 342 40 973 2,942 552
  Net Cash Provided By Used In Investing Activities -48,263 -103,900 - - - -186,006 -297,616 -444,815
Net Cash Provided By Used In Financing Activities
  Proceeds From Long Term Lines Of Credit 37,000 72,000 191,000 372,000 112,000 173,696 260,000 404,000
  Paymentof Contingent Consideration - - - - - - 6,329 7,039
  Paymentofpurchasecontingentconsideration - - 0 601 0 0 - -
  Payments To Minority Shareholders - 0 0 601 - - - -
  Repayments Of Long Term Lines Of Credit 78,000 50,000 100,000 126,000 159,000 132,000 170,000 190,877
  Net Cash Provided By Used In Financing Activities Continuing Operations - -10,669 78,427 103,208 -160,115 27,336 56,772 -
  Excess Tax Benefit From Share Based Compensation Financing Activities 669 6,346 12,110 5,126 93 1,402 881 -
  Payments For Repurchase Of Redeemable Noncontrolling Interest 795 7,241 7,616 16,610 1,243 0 3,600 3,848
  Common Stock Issued Repurchased And Retired Related To Stock Option Exercises 681 14,298 307 2,364 273 5 - -
  Payments Of Dividends Minority Interest 10,360 14,893 9,090 7,579 79,212 9,699 19,017 18,401
  Payments Of Dividends Common Stock 3,546 4,494 5,689 120,361 31,215 9,343 10,724 12,807
  Payments Of Debt Issuance Costs 0 0 3,028 570 767 0 0 270
  Proceeds From Stock Options Exercised 1,815 2,167 833 463 708 3,673 5,924 5,659
  Proceeds From Payments For Other Financing Activities -294 -256 214 -296 -1,206 -388 -364 -545
  Net Cash Provided By Used In Financing Activities -54,192 -10,669 - - - 27,336 56,772 175,872
Effect Of Exchange Rate On Cash And Cash Equivalents 114 8 -353 312 -657 -819 1,012 3,169
Cash And Cash Equivalents Period Increase Decrease -624 10,957 3,951 -5,952 4,730 13,374 9,352 9,111
Cash And Cash Equivalents At Carrying Value - - - 15,499 20,229 33,603 42,955 52,066

Peers - Aircraft Engines and Engine Parts (3724)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 422806109